Completed
An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
NCT00250627
- Conditions
- Behavior, Behavioral Symptoms, Depression, +3 more
- Locations
-
- Sanofi-Aventis Administrative Office Laval, Canada
- Sanofi-Aventis Administrative Office Santiago, Chile
- Sanofi-Aventis Administrative Office Zagreb, Croatia
- Sanofi-Aventis Administrative Office Prague, Czechia